Safety of lamivudine treatment for chronic hepatitis B in early pregnancy

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 45

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Dec 7, 2012; 18(45): 6645-6650
Published online Dec 7, 2012. doi: 10.3748/wjg.v18.i45.6645

Table 1 Clinical information of mothers who took lamivudine treatment before or during early pregnancy n (%)

	Treated population (n = 92)
Average age (yr)	30.5 ± 3.1
Primipara	88 (95.7)
Cirrhosis	2 (2.2)
HBeAg positivity rate	74 (80.4)
HBV DNA > 10⁵ copies/mL in early pregnancy	16 (17.4)
Treatment before pregnancy
Naive	15 (16.3)
LAM	41 (44.6)
ADV	28 (30.4)
LAM→ADV	3 (3.3)
ETV	2 (2.2)
ETV→ADV	1 (1.1)
IFN + LdT	2 (2.2)

LAM: Lamivudine; ADV: Adefovir dipivoxil; ETV: Entecavir; LdT: Telbivudine; IFN: Interferon; HBeAg: Hepatitis B e antigen.

Citation: Yi W, Liu M, Cai HD. Safety of lamivudine treatment for chronic hepatitis B in early pregnancy. World J Gastroenterol 2012; 18(45): 6645-6650
URL: https://www.wjgnet.com/1007-9327/full/v18/i45/6645.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i45.6645

Yi W, Liu M, Cai HD. Safety of lamivudine treatment for chronic hepatitis B in early pregnancy. World J Gastroenterol 2012; 18(45): 6645-6650 [PMID: 23236240 DOI: 10.3748/wjg.v18.i45.6645]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.